Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324) ...Middle East

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an...

Read More Details
Finally We wish PressBee provided you with enough information of ( Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324) )

Also on site :

• 7 pet-friendly Colorado hotels for your next getaway or roadtrip
• The Mid-Morning Habit Cardiologists Are Begging You to Never, Ever Do
• Chipotle’s new CEO is bringing back a missing ingredient to hit the chain’s next goal—raising annual sales per store to $4 million